The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Abstract
Objective: To evaluate the efficacy and safety of intraarticular sprifermin (recombinant human fibroblast growth factor 18) in the treatment of symptomatic knee osteoarthritis (OA). Methods: The study was a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial. Intraarticular sprifermin was evaluated at doses of 10 μg, 30 μg, and 100 μg. The primary efficacy end point was change in central medial femorotibial compartment cartilage thickness at 6 months and 12 months as determined using quantitative magnetic resonance imaging (qMRI). The primary safety end points were nature, incidence, and severity of local and systemic treatment‐emergent adverse events (AEs) and acute inflammatory reactions, as well as results of laboratory assessments. Secondary end points included changes in total and compartment femorotibial cartilage thickness and volume as assessed by qMRI, changes in joint space width (JSW) seen on radiographs, and pain scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results: One hundred ninety‐two patients were randomized and evaluated for safety, 180 completed the trial, and 168 were evaluated for the primary efficacy end point. We found no statistically significant dose response in change in central medial femorotibial compartment cartilage thickness. Sprifermin was associated with statistically significant, dose‐dependent reductions in loss of total and lateral femorotibial cartilage thickness and volume and in JSW narrowing in the lateral femorotibial compartment. All groups had improved WOMAC pain scores, with statistically significantly less improvement at 12 months in patients receiving the 100‐μg dose of sprifermin as compared with those receiving placebo. There was no significant difference in serious AEs, treatment‐emergent AEs, or acute inflammatory reactions between sprifermin and placebo groups. Conclusion: No statistically significant relationship between treatment group and reduction in central medial femorotibial compartment cartilage thickness was observed; however, prespecified structural secondary end points showed statistically significant dose‐dependent reductions after sprifermin treatment. Sprifermin was not associated with any local or systemic safety concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiological Assessment of Osteo-Arthrosis
Kellgren, J. H., & Lawrence, J. S. (1957) · Annals of the Rheumatic Diseases · doi:10.1136/ard.16.4.494 · Cited by 12,422
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
OARSI recommendations for the management of hip and knee osteoarthritis
Zhang, W., Nuki, G., Moskowitz, R. W., Abramson, S., Altman, R. D., Arden, N. K., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.013 · Cited by 1,700
Self-citationWhole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis
Peterfy, C. G., Guermazi, A., Zaim, S., Tirman, P. F. J., Miaux, Y., White, D., Kothari, M., Lu, Y., Fye, K., Zhao, S., et al. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.11.003 · Cited by 1,540
Self-citationAtlas of individual radiographic features in osteoarthritis, revised
Altman, R. D., & Gold, G. E. (2007) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.11.009 · Cited by 1,372
Reginster, J. Y., Deroisy, R., Rovati, L. C., Lee, R. L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J. E., & Gossett, C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03610-2 · Cited by 1,234
Pavelká, K., Gatterová, J., Olejarová, M., Machacek, S., Giacovelli, G., & Rovati, L. C. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2113 · Cited by 683
Osteoarthritis as a disease of mechanics
Felson, D. T. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.09.012 · Cited by 676
Cited by
Glyn-Jones, S., Palmer, A. J. R., Agricola, R., Price, A. J., Vincent, T. L., Weinans, H., & Carr, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60802-3 · Cited by 3,151
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Intra-articular treatment options for knee osteoarthritis
Jones, I. A., Togashi, R., Wilson, M. L., Heckmann, N., & Vangsness, C. T. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0123-4 · Cited by 525
Toh, W. S., Lai, R. C., Hui, J. H. P., & Lim, S. K. (2017) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.11.008 · Cited by 502
Krishnan, Y., & Grodzinsky, A. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.005 · Cited by 443
Metadata
- Authors
- Lohmander, L. S., Hellot, S., Dreher, D., Krantz, E. F. W., Kruger, D. S., Guermazi, A., & Eckstein, F.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-06-27
- Volume
- 66
- Issue
- 7
- Pages
- 1820-1831
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2148857381
- Cited by
- 275
- References
- 45
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double‐Blind, Placebo‐Controlled Trial. https://app.cochat.ai/papers/10.1002/art.38614
- The paper
- Lohmander, L. S., Hellot, S., Dreher, D., Krantz, E. F. W., Kruger, D. S., Guermazi, A., & Eckstein, F. (2014). Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.38614
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.